🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Compugen (CGEN)

Tel Aviv
Currency in ILS
593.3
+6.2(+1.06%)
Closed
CGEN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
580.1599.8
52 wk Range
263.21,175.0
Key Statistics
Edit
Bid/Ask
589.10 / 591.20
Prev. Close
587.1
Open
587.1
Day's Range
580.1-599.8
52 wk Range
263.2-1,175
Volume
108.83K
Average Volume (3m)
110.29K
1-Year Change
96.16%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CGEN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compare CGEN to Peers and Sector

Metrics to compare
CGEN
Peers
Sector
Relationship
P/E Ratio
92.4x−2.9x−0.7x
PEG Ratio
0.88−0.020.00
Price/Book
2.4x2.5x2.6x
Price / LTM Sales
2.5x72.1x3.2x
Upside (Analyst Target)
-308.8%47.0%
Fair Value Upside
Unlock14.7%7.5%Unlock

People Also Watch

6,100
TEVA
-2.35%
379.20
MSTR
-4.00%
93.7
ORL
+1.41%
19,550
ELWS
+4.88%
780.0
ARYT
-0.10%

FAQ

What Is the Compugen (CGEN) Stock Price Today?

The Compugen stock price today is 593.30

What Stock Exchange Does Compugen Trade On?

Compugen is listed and trades on the Tel Aviv stock exchange.

What Is the Stock Symbol for Compugen?

The stock symbol for Compugen is "CGEN."

What Is the Compugen Market Cap?

As of today, Compugen market cap is 511.49M.

What is Compugen Earnings Per Share?

The Compugen EPS is 0.018.

What Is the Next Compugen Earnings Date?

Compugen will release its next earnings report on Feb 19, 2025.

From a Technical Analysis Perspective, Is CGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.